Infectious Diseases Research

Below are current clinical trials.

271 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

   Rochester, Minn.

   Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group II. The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI in adults up to 8 weeks after initiation of treatment.

2. Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

   Rochester, Minn.

   This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes. Patients who have had at least two recurrences after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization within the last year may be eligible for the study. Subjects who are deemed failures following the blinded treatment per the pre-specified treatment failure definition may elect to receive an unblinded RBX2660 enema.

3. Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

   Scottsdale/Phoenix, Ariz.

   This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C. difficile infection (CDI) after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Patients whose CDI returns in less than 8 weeks after the last assigned study treatment may be eligible to receive up to 2 treatments with RBX2660 in the open-label portion of the study.

4. A Study to Measure SARS-CoV-2 RNA in Human Saliva

   Rochester, Minn.

   The purpose of this study is to collect saliva specimens from individuals who tested positive for SARS-CoV-2 RNA in respiratory tract specimens to validate this specimen type for the SARS-Co-V-2 RNA Detection and Quantification digital droplet PCR-based assay, and to evaluate the use of SARS-CoV-2 viral load measured in saliva for correlation with levels in other specimen types, disease course, and/or response to therapy.

    

5. A Study to Evaluate Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

   Jacksonville, Fla.

   The purpose of this study is to evaluate microbiota suspension of intestinal microbes. Patients who have had at least one recurrence of Clostridium Difficile Infection (CDI) after a primary episode and have completed at least one round of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Subjects may receive a second RBX2660 enema if they are deemed treatment failures following the initial enema per the protocol-specified treatment failure definition.

6. A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Participants with Mycobacterium Avium Complex (MAC) Pulmonary Disease

   Rochester, Minn.

   The purpose of the study is to evaluate the microbiological response and clinical effectiveness of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). Additionally, to determine the safety and tolerability of SPR720 in a participants population with NTM- PD 3. Also, the pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in a participant population with NTM-PD.

7. A Study to Evaluate a Resiliency Program for Healthcare Professionals During a Pandemic

   Rochester, Minn.

   The purpose of this study is to evaluate the feasibility of a resiliency program to provide an effective and sustainable solution to several important problems experienced by medical professionals.

8. Treatment burden, stress, and coping in the context of social distancing: A qualitative study of patients with diabetes mellitus

   Rochester, Minn.

   The purpose of this study is to track the treatment burden experienced by patients living with Type 2 Diabetes Mellitus (T2DM) experience as they work to manage their illness in the context of social distancing measures. 

    

   To promote social distancing during the COVID-19 pandemic, health care institutions around the world have rapidly expanded their use of telemedicine to replace in-office appointments where possible.1 For patients with diabetes, who spend considerable time and energy engaging with various components of the health care system,2,3 this unexpected and abrupt transition to virtual health care may signal significant changes to the treatment burden associated with diabetes management.4 Previous research has characterized the effect of telemedicine approaches on outcomes such as glycemic control, patient satisfaction, cost savings, and appointment adherence rates,5-8 but its influence on treatment burden has not been explored. Importantly, work in this area has largely drawn from the experiences of patients who voluntarily selected to use virtual health services. The current situation, in which patients with chronic health conditions have been obligated to use telemedicine in order to receive care, therefore presents a unique opportunity to explore the ways in which virtual diabetes management impacts the workload associated with managing chronic illness.

   Aim: Explore patient experiences managing diabetes mellitus in the context of recent widespread changes in healthcare and social distancing due to the novel coronavirus pandemic, including barriers and facilitators to obtaining needed health care services and changes in social networks. To accomplish this aim, we will conduct qualitative interviews with up to 30 participants.

    

9. Screening for Sleep Disordered Breathing and Sleep Disturbance Among Patients Recovered from COVID Infection

   Jacksonville, Fla.

   The purpose of this study is to compare prevalence of sleep apnea and sleep disturbance in post-COVID-19 infected patients who had been symptomatic to COVID negative participants as controls. A sleep testing device will assess for sleep disordered breathing and the results will be aggregated to compare if a significant increase (any difference) in the prevalence of sleep disordered breathing diagnosis between the two groups. Sleep questionnares data will be obtained. A second part of this study will involve using a Fitbit consumer wearable device to obtain sleep and activity data on participants for 2 months in duration. 

10. A Study to Characterize the Genetic Profile of Karyomegalic Interstitial Nephritis (KIN) to Find Better Ways of Diagnosis and Treatment

    Rochester, Minn., Jacksonville, Fla.

    The purpose of this study is to describe the clinicopathological features and characterize the genetic variants (by Whole exome sequencing).